Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption

Advanced Drug Delivery Reviews

Volumn 25, Issue 2-3, 1997, Pages 129-157

  Hunter, Janice ^a   Hirst, Barry H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cytochrome P 450; Drug absorption; Intestine; Multidrug resistance; Oral bioavailability; P glycoprotein

Indexed keywords

ABSORPTION; DRUG INTERACTIONS; DRUG PRODUCTS; METABOLISM; PHARMACOKINETICS; PROTEINS;

CYTOCHROME; GLYCOPROTEIN; INTESTINAL SECRETION; MULTIDRUG RESISTANCE; ORAL BIOAVAILABILITY; ORAL DRUG ABSORPTION;

DRUG THERAPY;

AMOXICILLIN; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CARDIAC GLYCOSIDE; CELIPROLOL; CINOXACIN; CIPROFLOXACIN; CYCLOSPORIN DERIVATIVE; DIGOXIN; GLYCOPROTEIN P; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE DERIVATIVE; INDOLE ALKALOID; INTERCALATING AGENT; LOCAL ANESTHETIC AGENT; METHOTREXATE; PHENOTHIAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; INTESTINE SECRETION; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0343488673     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00497-3     Document Type: Review

References (192)

1. Simons, K. and Fuller, S.D. (1985) Cell surface polarity in epithelia. Ann. Rev. Cell Biol. 1, 243-288.
2. Bjarnson, I., Macpherson, A. and Hollander, D. (1995) Intestinal permeability: an overview. Gastroenterology 108, 1566-1581.
3. Tidball, C.S. (1971) The nature of the intestinal barrier. Dig. Dis. 16, 745-767.
4. Collares-Buzato, C.B., Jepson, M.A., McEwan, G.T., Simmons, N.L. and Hirst, B.H. (1994) Junctional uvomorulin/Ecadherin and phosphotyrosine-modified protein content are correlated with the paracellular permeability in Madin-Darby canine kidney (MDCK) epithelia. Histochemistry 101, 185-194.
5. 2+ in cultured epithelia. Biochim. Biophys. Acta 1222, 147-158.
6. Dayton, P.G., Israili, Z.H. and Henderson, J.D. (1983) Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract. Drug Metab. Rev. 14, 1193-1206.
7. Israili, Z.H. and Dayton, P.G. (1984) Enhancement of xenobiotic elimination: role of intestinal excretion. Drug Metab. Rev. 15, 1123-1159.
8. Kararli, T.T. (1989) Gastrointestinal absorption of drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 39-86.
9. Lieb, W.R. and Stein, W.D. (1971) Implications of two different types of diffusion for biological membranes. Nature New Biol. 234, 220-222.
10. Alcorn, C.J., Simpson, R.J., Leahy, D.E. and Peters, T.J. (1993) Partition and distribution coefficients of solutes and drugs in brush border membrane vesicles. Biochem. Pharmacol. 45, 1775-1782.
11. Aungst, B.J. (1993) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82, 979-987.
12. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Wyvill, K.M., Flora, K.P., Broder, S. and Johns, D.G. (1991) Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effect of different oral formulations and the presence of other medications. Clin. Pharmacol. Ther. 50, 278-285.
13. Illing, H.P. (1981) Techniques for microfloral and associated metabolic studies in relation to the absorption and enterohepatic circulation of drugs. Xenobiotica 11, 815-830.
14. Rowland, I.R. (1986) Reduction by the gut microflora of animals and man. Biochem. Pharmacol. 35, 27-32.
15. Hartiala, K. (1973) Metabolism of hormones, drugs and other substances by the gut. Physiol. Rev. 53, 496-534.
16. Ilett, K.F., Tee, L.B., Reeves, P.T. and Minchin, R.F. (1990) Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol. Ther. 46, 67-93.
17. Hillgren, K.M., Kato, A. and Borchardt, R.T. (1995) In vitro systems for studying intestinal drug absorption. Med. Res. Rev. 15, 83-109.
18. Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268, 14991-14997.
19. Hunter, J., Hirst, B.H. and Simmons, N.L. (1991) Transepithelial vinblastine secretion mediated by P-glycoprotein is inhibited by forskolin derivatives. Biochem. Biophys. Res. Commun. 181, 902-910.
20. Griffiths, N.M., Hirst, B.H. and Simmons, N.L. (1993) Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br. J. Pharmacol. 108, 575-576.
21. Collington, G.K., Hunter, J., Allen, C.A., Simmons, N.L. and Hirst, B.H. (1992) Polarized efflux of 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers. Biochem. Pharmacol. 44, 417-424.
22. Kim, D.C., Harrison, A.W., Ruwart, M.J., Wilkinson, K.F., Fisher, J.F., Hidalgo, I.J. and Borchardt, R.T. (1993) Evaluation of the bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides. J. Drug Targeting 1, 347-359.
23. Hu, M. and Borchardt, R.T. (1990) Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm. Res. 7, 1313-1319.
24. +-coupled amino acid transporter. Br. J. Pharmacol. 115, 761-766.
25. Inui, K., Yamamoto, M. and Saito, H. (1992) Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes. J. Pharmacol. Exp. Ther. 261, 195-201.
26. Saitoh, H. and Aungst, B.J. (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12, 1304-1310.
27. Hidalgo, I.J., Bhatnager, P., Lee, C.P., Miller, J., Cucullino, G. and Smith, P.L. (1995) Structural requirements for interaction with oligopeptide transporter in Caco-2 cells. Pharm. Res. 12, 317-319.
28. Thwaites, D.T., Cavet, M., Hirst, B.H. and Simmons, N.L. (1995) Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 114, 981-986.
29. Jepson, M.A., Clark, M.A., Foster, N., Mason, C.M., Bennett, M.K., Simmons, N.L. and Hirst, B.H. (1996) Targeting to intestinal M cells. J. Anat. 189 (in press).
30. Bellamy, W.T. (1996) P-glycoprotein and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 36, 161-183.
31. Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu: Rev. Biochem. 62, 385-427.
32. Goldstein, L.J., Pastan, I. and Gottesman, M.M. (1992) Multidrug resistance in human cancer. Crit. Rev. Oncol. Hematol. 12, 243-253.
33. Morrow, C.S. and Cowan, K. (1993) Drug resistance and cancer. In: S.S. Yang and H.R. Warner (Eds), The Underlying Molecular, Cellular and Immunological Factors in Cancer and Aging. Plenum Press, New York, pp. 287-305.
34. Shen, D.-W., Fojo, A., Chin, J.E., Roninson, I.B., Richert, N., Pastan, I. and Gottesman, M.M. (1986) Multiply drug resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261, 7762-7770.
35. Kartner, N., Riordan, J.R. and Ling, V. (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288.
36. Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M. and Roninson, I.B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr-1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 47, 381-389.
37. Shen, D.W., Fojo, A., Roninson, I.B., Chin, J.E., Soffir, R., Pastan, I. and Gottesman, M.M. (1986) Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol. Cell. Biol. 6, 4039-4044.
38. Ueda, K., Cardarelli, C., Gottesman, M.M. and Pastan, I. (1987) Expression of a full length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 84, 3004-3008.
39. Ling, V. and Thompson, L. (1973) Reduced permeability in CHO cells as a mechanism of resistance to coichicine. J. Cell. Physiol. 83, 103-116.
40. Hyde, S.C., Emsley, P., Hartshorn, M.J., Mimmack, M.M., Gileadi, U., Pearce, S.R., Gallagher, M.P., Hubbard, R. and Higgins, C.F. (1990) Structural and functional relationships of ATP-binding proteins associated with cystic fibrosis multidrug resistance and bacterial transport. Nature 346, 362-365.
41. Higgins, C.F. (1992) ABC transporters - from microorganisms to man. Ann. Rev. Cell Biol. 8, 67-113.
42. Beck, W.T. and Qian, X.-D. (1992) Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol. 43, 89-93.
43. Ruetz, S. and Gros, P. (1994) Functional expression of P-glycoprotein in secretory vesicles. J. Biol. Chem. 269, 12277-12284.
44. Cornwell, M.M., Gottesman, M.M. and Pastan, I.H. (1986) Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J. Biol. Chem. 261, 7921-7928.
45. Horio, M., Lovelace, E., Pastan, I. and Gottesman, M.M. (1991) Agents which reverse multidrug resistance are inhibitors of vinblastine transport by isolated vesicles. Biochim. Biophys. Acta 1061, 106-110.
46. Horio, M., Chin, K.-V., Currier, S.J., Goldenberg, S., Williams, C., Pastan, I., Gottesman, M.M. and Handler, J. (1989) Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264, 14880-14884.
47. Shimabuku, A.M., Nishimoto, T., Ueda, K. and Komano, T. (1992) P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain. J. Biol. Chem. 267, 4308-4311.
48. r 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 48, 4926-4932.
49. Sarkadi, B., Price, E.M., Boucher, R.C., Germann, U.A. and Scarborough, G.A. (1992) Expression of the human multidrug-resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267, 4854-4858.
50. Raviv, Y., Pollard, H.B., Bruggemann, E.P., Pastan, I. and Gottesman, M.M. (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265, 3975-3980.
51. Skovsgaard, T. (1978) Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38, 4722-4727.
52. Stein, W.D., Cardarelli, C., Pastan, I. and Gottesman, M.M. (1994) Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol. Pharmacol. 45, 763-772.
53. Ford, J.M. and Hait, W.N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
54. Zamora, J.M., Pearce, H.L. and Beck, W.T. (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33, 454-462.
55. Kessel, D. (1989) Exploring multidrug resistance using rhodamine 123. Cancer Commun. 1, 145-149.
56. Inaba, M., Kobayashi, H., Sakurai, Y and Johnson, R.K. (1979) Active efflux of daunorubicin and adriamycin in sensitive and resistant subline of P388 leukemia. Cancer Res. 39, 2200-2203.
57. Higgins, C.F. and Gottesman, M.M. (1992) Is the multidrug transporter a flippase? Trends Biochem. Sci. 17, 18-21.
58. van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P. and Van Meer, G. (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (in press).
59. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967-1972.
60. Sinicrope, F.A., Dudeja, P.K., Bissonette, B.M., Safa, A.R. and Brasitus, T.A. (1992) Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem. 267, 24995-25002.
61. Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G. Gottesman, M.M. and Pastan, I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 265-269.
62. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M. and Pastan, I. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735-7738.
63. Sugawara, I., Katoaka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. and Mori, S. (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res. 48, 1926-1929.
64. Arceci, R.J., Croop, J.M., Horwitz, S.V.B. and Housman, D. (1988) The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc. Natl. Acad. Sci. U.S.A., 85, 4350-4354.
65. Cordon-Cardo, C. and O'Brian, J.P. (1991) The multidrug resistance phenotype in human cancer. In: V.T. DeVita, S. Hellman and S.A. Rosenberg (Eds.), Important Advances in Oncology. Lippencott, Philadelphia, pp. 19-38.
66. Trezise, A.E., Romano, P.R., Gill, D.R., Hyde, S.C., Sepulveda, F.V., Buchwald, M. and Higgins, C.F. (1992) The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 11, 4291-4303.
67. Awasthi, S., Singhal, S.S., Srivastava, S.K., Zimniak, P., Bajpai, K.K., Saxena, M., Sharma, R., Ziller, S.A., Frenkel, E.P., Singh, S.V., He, N.G. and Awasthi, Y.C. (1994) Adenosine triphosphate-dependent transport of doxorubicin, daunomycin and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J. Clin. Invest. 93, 948-965.
68. Danks, M.K., Yalowich, J.C. and Beck, W.T. (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47, 1297-1301.
69. Danks, M.K., Schmidt, C.A., Cirtain, M.C., Suttle, D.P. and Beck, W.T. (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27, 8861-8869.
70. Grant, C.E., Valdimarsson, G. and Hipfner, E. (1994) Over-expression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54, 357-361.
71. Marquardt, D., McCrone, S. and Center, M.S. (1990) Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res. 50, 1426-1430.
72. Twentyman, P.R. and Versantvoort, C.H.M. (1996) Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur. J. Cancer 32A, 1002-1009.
73. Zaman, G.J.R., Flens, M.J., van Leusden, M.R., de Haas, M., Mulder, H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Baas, F., Broxterman, H.J. and Borst, P. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U.S.A. 91, 8822-8826.
74. Jedlitschky, G., Leier, I., Buchholz, U., Center, M. and Keppler, D. (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 54, 4833-4836.
75. Muller, M., Meijer, C. and Zaman, G.J.R. (1994) Over-expression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 91, 13027-13033.
76. 4 and structurally related conjugates. J. Biol. Chem. 265, 27807-27810.
77. Ishikawa, T. (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 17, 463-468.
78. Vincenzini, M.T., Favilli, F. and Iantoasi, T. (1992) Intestinal uptake and transmembrane transport systems of intact GSH; characteristics and possible biological role. Biochim. Biophys. Acta 1113, 13-23.
79. Allen, C.N., Harpur, E.S., Gray, T.J.B., Simmons, N.L. and Hirst, B.H. (1990) Efflux of bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-dependent transport mechanism in epithelial cells. Biochem. Biophys. Res. Commun. 172, 262-267.
80. Liminga, G., Nygren, P. and Larsson, R. (1994) Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp. Cell Res. 212, 291-296.
81. Wall, D.M., Hu, X.F., Zalcberg, J.R. and Parkin, J.D. (1991) Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator Fluo-3. J. Natl. Cancer Inst. 83, 206-207.
82. Wall, D.M., Sparrow, R., Hu, X.F., Nadalin, G., Zalcberg, J.R., Marschner, I.C., Van der Weyden, M. and Parkin, J.D. (1993) Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, Fluo-3. Eur. J. Cancer 29A, 1024-1027.
83. Weinstein, G.D. (1977) Methotrexate. Ann. Intern. Med. 86, 199-204.
84. Jolivet, J., Cowan, K.H., Curt, G.A., Clendeninn, N.J. and Chabner, B.A. (1983) The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309, 1094-1104.
85. Willkins, R.F. and Watson, M.A. (1982) Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J. Lab. Clin. Med. 100, 314-321.
86. Mullarkey, M.F., Blumstein, B.A., Andrade, W.P., Bailey, G.A., Olason, I. and Wetzel, C.E. (1988) Methotrexate in the treatment of corticosteroid-dependent asthma. N. Engl. J. Med. 109, 603-607.
87. Kaplan, M.M., Knox, T.A. and Arora, S. (1988) Primary biliary cirrhosis treated with low dose oral pulse methotrexate. Ann. Intern. Med. 109, 429-431.
88. Kozarek, R.A., Patterson, D.J., Gelfand, M.D., Botoman, V.A., Ball, T.J. and Wilske, K.R. (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann. Intern. Med. 110, 353-356.
89. Chabner, B.A., Clendeninn, N., Curt, G.A. and Jolivet, J. (1986) Biochemistry of methotrexate. In: K. Kimura and Y.M. Wang (Eds.), Methotrexate in Cancer Chemotherapy. Raven Press, New York, pp. 1-38.
90. Bertino, J.R. and Wang, Y.M. (1986) Mechanisms of acquired methotrexate resistance in humans. In: K. Kimura and Y.M. Wang (Eds.), Methotrexate in Cancer Chemotherapy. Raven Press, New York, pp. 125-131.
91. Selhub, J., Dhar, G.J. and Rosenberg, I.H. (1983) Gastrointestinal absorption of folates and antifolates. Pharmacol. Ther. 20, 397-418.
92. Said, H.M., Ghishan, F.K. and Redha, R. (1987) Folate transport by human intestinal brush border membrane vesicles. Am. J. Physiol. 252, G229-G236.
93. Zimmerman, J. (1992) Methotrexate transport in the human intestine. Biochem. Pharmacol. 43, 2377-2383.
94. Zimmerman, J. (1990) Folic acid transport in organ-cultured mucosa of human intestine. Evidence for distinct carriers. Gastroenterology 99, 964-972.
95. Sirotnak, F.M. and O'Leary (1991) The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors. Cancer Res. 51, 1412-1417.
96. Henderson, G.B. and Tsuji, J.M. (1988) Identification of the bromosulfophthaline-sensitive efflux route for methotrexate as the site of action of vincristine in the vincristine-dependent enhancement of methotrexate uptake in L1210 cells. Cancer Res. 48, 5995-6001.
97. Gleeson, D. (1992) Acid-base transport systems in gastrointestinal epithelia. Gut 33, 1134-1145.
98. Thomson, A.B.R. and Dietschy, J.M. (1984) The role of the unstirred water layer in intestinal permeation. In: T.Z. Csaky (Ed.), Pharmacology of Intestinal Permeation II. Springer-Verlag, New York, pp. 165-269.
99. Westergaard, H. and Dietschy, J.M. (1974) Delineation of the dimensions and permeability characteristics of the two major diffusion barriers to passive mucosal uptake in the rabbit intestine. J. Clin. Invest. 54, 718-732.
100. Lucas, M.L., Schneider, W., Harberrich, F.J. and Blair, J.A. (1975) Direct measurement by pH-microelectrode of the pH microclimate in rat proximal jejunum. Ibid. 192, 39-48.
101. Lucas, M.L. and Blair, J.A. (1978) The magnitude and distribution of the acid microclimate in proximal jejunum and its relation to luminal acidification. Proc. R. Soc. Lond. 200, 27-41.
102. Holland, D.R. and Quay, J.F. (1976) Intestinal secretion of erythromycin base. J. Pharm. Sci. 65, 417-419.
103. Turnheim, K. and Lauterbach, F. (1980) Interaction between intestinal absorption and secretion of monoquaternary ammonium compounds in guinea pigs - A concept for the absorption kinetics of organic cations. J. Pharmacol. Exp. Ther. 212, 418-424.
104. Huang, J.-D. (1990) Comparative drug exorption in the perfused rat intestine. J. Pharm. Pharmacol. 42, 167-170.
105. Cho, M.J., Thompson, D.P., Cramer, C.T., Vidmar, T.J. and Scieszka, J.F. (1989) The Madin-Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm. Res. 6, 71-77.
106. Pinto, M., Robine-Leon, S., Appay, M.D., Kedinger, M., Traidou, N., Dussaulx, E., Lacroix, B., Simon-Assmann, P., Haffan, K., Fogh, J. and Zweibaum, A. (1983) Enterocytelike differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47, 323-330.
107. Hidalgo, I.J., Raub, T.J. and Borchardt, R.T. (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96, 736-749.
108. Audus, K.L., Bartel, R.L., Hidalgo, I.J. and Borchardt, R.T. (1990) The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. 7, 435-451.
109. Ranaldi, G., Islam, K. and Sambuy, Y. (1992) Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 36, 1374-1381.
110. Wils, P., Warney, A., Phung-Ba, V. and Scherman, D. (1994) Differentiated intestinal cell lines as in vitro models for predicting the intestinal absorption of drugs. Cell Biol. Toxicol. 10, 393-397.
111. Madara, J.L., Stafford, J., Dharmsathaphorn, K. and Carlson, S. (1983) Structural analysis of a human intestinal epithelial cell line. Gastroenterology 92, 1133-1145.
112. Chantret, I., Barbat, A., Dussaulx, E., Brattain, M.G. and Zweibaum, A. (1988) Epithelial polarity, villin expression and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 48, 1936-1942.
113. Riley, S.A., Warhurst, G., Crowe, P.T. and Turnberg, L.A. (1991) Active hexose transport across cultured human Caco-2 cells: characterisation and influence of culture conditions. Biochim. Biophys. Acta 1066, 175-182.
114. Hu, M. and Borchardt, R.T. (1992) Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. Biochim. Biophys. Acta 1135, 233-244.
115. +-coupled carriers at both apical and basal membranes. J. Biol. Chem. 268, 7640-7642.
116. Kim, D.C., Burton, P.S. and Borchardt, R.T. (1993) A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 10, 1710-1714.
117. Wils, P., Phung-Ba, V., Warney, A., Lechardeur, D., Raeissi, S., Hidalgo, I.J. and Scherman, D. (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cells. Biochem. Pharmacol. 48, 1528-1530.
118. 1 intestinal cells: a new model for studying the epithelial transport of drugs. Biochim. Biophys. Acta 1177, 134-138.
119. Hunter, J., Hirst, B.H. and Simmons, N.L. (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10, 743-749.
120. Pereira, E., Borrel, M.N., Fiallo, M. and Garnier-Suillerot, A. (1994) Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Biochim. Biophys. Acta 1225, 209-216.
121. m of the pump. Biochim. Biophys. Acta 1027, 116-122.
122. Spoelstra, E.C., Westerhoff, H.V., Dekker, H. and Lankelma, J. (1992) Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur. J. Biochem. 207, 567-579.
123. Tamai, I. and Safa, A.R. (1990) Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265, 16509-16513.
124. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42, 4730-4733.
125. Artursson, P. and Karlsson, J. (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175, 880-885.
126. Gerzon, K., Ochs, S. and Todd, G.C. (1979) Polarity of vincristine (VCR), vindesine (VDS), and vinblastine (VBL) in relation to neurological effects. Proceedings of AACR and ASCO Abstracts, 186, p. 46.
127. Augustijns, P.F., Bradshaw, T.P., Gan, L.-S.L., Hendren, R.W. and Thakker, D.R. (1993) Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197, 360-365.
128. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. and Beglinger, C. (1996) Relevance of P-glycoprotein for the enterai absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118, 1841-1847.
129. Pastan, I. and Gottesman, M.M. (1991) Multidrug resistance. Ann. Rev. Med. 42, 277-286.
130. Yusa, K. and Tsuruo, T. (1989) Reversal mechanism of multidrug resistance by verapamil; direct binding of verapamit to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ ADM cells. Cancer Res. 49, 5002-5006.
131. Burton, P.S, Conradi, R.A., Hilgers, A.R. and Ho, N.F.H. (1993) Evidence for a polarized efflux system for peptides in the apical membrane of CaCo-2 cells. Biochem. Biophys. Res. Commun. 190, 760-766.
132. Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1996) The use of sufactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13, 528-534.
133. Sharma, R.C., Inoue, S., Roitelman, J., Schimke, R.T. and Simon, R.D. (1992) Peptide transport by the multidrug resistance pump. J. Biol. Chem. 267, 5731-5734.
134. Pedersen, K.E., Thayssen, P., Kiltgaard, N.A., Christiansen, B.D. and Nielsen-Kudsk, F. (1983) Influence of verapamil on the inotropism and pharmacokinetics of digoxin. Eur. J. Pharmacol. 25, 199-206.
135. Westphal, J.-F., Trouvin, J.-H., Deslandes, A. and Carbon, C. (1990) Nifedipine enhances amoxicillin absorption kinetics and bioavailability in humans. J. Pharmacol. Exp. Ther. 255, 312-317.
136. Belz, G.G., Wittich, M.D., Doering, M.D., Munkes, R. and Matthews, J. (1983) Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin. Pharmacol, Ther. 33, 410-417.
137. Rietbrock, N. and Woodcock, B.G. (1989) Handbook of Renal-independent Cardiac Glycosides; Pharmacology and Clinical pharmacology. Ellis Horwood, Chichester, pp. 71-94.
138. Lauterbach, F. (1981) Intestinal absorption and secretion of cardiac glycosides. In: K. Greef (Ed.), Cardiac glycosides, Part II. Springer-Verlag, Berlin, Heidelberg, New York, pp. 105-139.
139. Cavet, M., West, M. and Simmons, N.L. (1996) Transport and epithelial secretion of the cardiac glycoside digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118, 1389-1396.
140. 1). J. Pharmacol. Exp. Ther. 263, 840-845.
141. Suttle, A.B. and Brouwer, K.L.R. (1995) Regional gastrointestinal absorption of ranitidine in the rat. Pharm. Res. 12, 1311-1315.
142. Kirch, W., Hoensch, H. and Janisch, H.D. (1984) Interactions and non-interactions with ranitidine. Clin. Pharmacokinet. 9, 493-510.
143. 2 receptor antagonist ranitidine in human intestinal epithelial Caco-2 monolayers is mediated by P-glycoprotein. J. Physiol. 479, 103P.
144. Sorgel, F., Naber, K.G., Jaehde, U., Reiter, A., Seelmann, R. and Sigl, G. (1989) Gastrointestinal secretion of ciprofloxacin. Am. J. Med. 87 (suppl. 5A) 62S-65S.
145. Kinzig, M., Seelman, R., Mahr, G., Sorgel, F., Naber, E., Weidekamm, E. and Stockel, K. (1991) Significant gastrointestinal secretion of fleroxacin in man. Int. Congress Chemother. 388P.
146. Griffiths, N.M., Hirst, B.H. and Simmons, N.L. (1994) Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269, 496-502.
147. Riddel, J.G., Shanks, R.G. and Brogden, R.N. (1987) Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34, 438-458.
148. Kuo, S.-M., Whitby, B.R., Artursson, P. and Ziemniak, J.A. (1993) The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm. Res. 11, 648-653.
149. Gluth, W.P., Sorgel, F., Geldmacher, V. and Mallinckrodt, M. (1983) Celiprolol kinetics in healthy volunteers after oral dosing. Naunyn-Schmiedeberg's Arch. Pharmacol., 324 (Suppl.), R77.
150. Hitzenberger, G., Takacs, F. and Pittner, H. (1983) Pharmacokinetics of the beta adrenergic blocking substance celiprolol after single intravenous and oral administration in man. Drug Res. 33, 50-52.
151. Caruso, F.S., Doshan, H.D., Hernandez, P.H., Costello, R., Applin, W. and Neiss, E.S. (1985) Celiprolol; pharmacokinetics and duration of pharmacodynamic activity. Br. J. Clin. Pract. 39 (Suppl 40), 12-15.
152. Karlsson, J., Kuo, S.-M., Ziemniak, J. and Artursson, P. (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110, 1009-1016.
153. George, C.F. and Gruchy, B.S. (1979) Elimination of drugs by active intestinal transport. J. Pharm. Pharmacol. 31, 643-644.
154. 14C polyethylene glycol (PEG) 4000. Pharm. Res. 10, 130-135.
155. Lennernas, H. and Regardh, C.-G. (1993) Dose dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm. Res. 10, 727-731.
156. Walte, S. (1985) Comparative investigation on the relative bioavailability of celiprolol and chlorthalidone after single oral administration in man. Sci. Pharmacol. 53, 59.
157. Weterich, U., Spahn-Langguth, H., Mutschier, E., Terhang, B., Rosch, W. and Langguth, P.O. (1996) Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13, 514-522.
158. Raderer, M. and Scheithauer, W. (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72, 3553-3563.
159. Leveque, D. and Jehl, F. (1995) P-glycoprotein and pharmacokinetics. Anticancer Res. 15, 331-336.
160. Fisher, G.A., Lum, B.L., Hausdorff, J. and Sikic, B.I. (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 32A, 1082-1088.
161. Ferry, D.R., Glossman, H. and Kaumann, A.J. (1985) Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br. J. Pharmacol. 84, 811-824.
162. Gruber, A., Peterson, C. and Reizenstein, P. (1988) D-Verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int. J. Cancer 41, 224-226.
163. Plumb, J.A., Milroy, R. and Kaye, S.B. (1990) The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem. Pharmacol. 39, 787-792.
164. Hollt, V., Kouba, M., Dietel, M. and Vogt, G. (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol. 43, 2601-2608.
165. Kerr, D.J., Graham, J. Cummings, J., Morrison, J.G., Thompson, G.G., Brobie, M.J. and Kaye, S.B. (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18, 239-242.
166. Mross, K., Hamm, K. and Hossfeld, D.K. (3993) Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother. Pharmacol. 31, 369-375.
167. Wilson, W.H., Bates, S.E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R.E., Jaffe, E.S., Steinberg, S.M., Herdt, J. and Chabner, B.A. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol. 13, 1995-2004.
168. Berg, S.L., Tolcher, A., O'Shaughnessy, J.A., Denicoff, A.M., Noone, M., Ognibene, F.P., Cowan, K.H. and Balis, F.M. (1995) Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol. 13, 2039-2042.
169. Fedeli, L., Colozza, M., Boschetti, E., Sabalich, I., Aristei, C., Guerciolini, R., Del Fevero, A., Rossetti, R., Tonato, M., Rambotti, P. and Davis, S. (1989) Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805-1811.
170. Linn, S.C., von Kalken, C.K., van Tellingen, O., van der Valk, P., van Groeningen, C.J., Kuiper, C.M., Pinedo, H.M. and Giaconne, G. (1994) Clinical and pharmacological study of multidrug resistance reversal with vinblastine and bepridil. J. Clin. Oncol. 12, 812-819.
171. Zhou, X.J., Placidi, M. and Rahmani, R. (1994) Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res. 14 (3A), 1017-1022.
172. Rahmani, R. and Zhou, X.J. (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 17, 269-281.
173. Lum, B.L., Kaubisch, S., Yahanda, A.M, Adler, K.M., Jew, L., Ehsan, M.N., Brophy, N.A., Halsey, J., Gosland, M.P. and Sikic, B.I. (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10, 1635-1642.
174. Bartlett, N.L., Lum, B.L., Fisher, G.A., Brophy, N.A., Ehsan, M.N., Halsay, J. and Sikic, B.I. (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 12, 835-842.
175. Erlichman, C., Moore, M., Thiessen, J.J., Kerr, I.G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C. and Bunting, P. (1993) Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 53, 4837-4842.
176. Barbui, T., Rambaldi, A., Parenzan, L., Zucchelli, M., Perico, N. and Remuzzi, G. (1992) Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 339, 1421.
177. Boote, D.J., Dennis, I.F., Twentyman, P.R., Osborne, R.J., Laburte, C., Hensel, S., Smyth, J.F., Brampton, M.H. and Bleehen, N.M. (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin Oncol. 14, 610-618.
178. Keller, R.P. Altermatt, H.J., Donatsch, P., Zihlmann, H., Laissue, J.A. and Hiestand, P.C. (1992) Pharmacological interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer 51, 433-438.
179. Hausdorff, J., Fisher, G.A. and Halsey, J. (1995) A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol. 14, 181-407.
180. Collins, H.L., Fisher, G.A. and Hausdorff, J. (1995) Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug-resistance modulator. Proc Am. Soc. Clin. Oncol. 14, 181-406.
181. Beck, W.T. and Kuttesch, J.F. (1992) Neurological symptoms associated with cyclosporin plus doxorubicin. Lancet 340, 496.
182. Shah, J.C., Chen, J.R. and Chow, D. (1992) Oral bioavailability and in situ absorption in rat. Int. J. Pharmacol. 84, 223-229.
183. Leu, B.-L. and Huang, J.D. (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 35, 432-436.
184. Bair, C.-H., Tang, M.-J., Huang, J.-D. (1992) Concentration-dependent exorption of quinidine in the rat intestine. J. Pharm. Pharmacol. 44, 659-662.
185. Bair, C.-H. and Huang, J.-D. (1992) Effect of theophylline on the intestinal clearance of drugs in rats. J. Pharm. Pharmacol. 44, 483-486.
186. Damm, K.H. and Woermann, C. (1974) The effect of probenecid on the in vitro absorption of cardiac glycosides. Eur. J. Pharmacol. 28, 157-163.
187. Oude Elferink, R.P., Bakker, C.T.M. and Jansen, L.M. (1993) Glutathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem. J. 290, 759-764.
188. Schuetz, E.R., Beck, W.T. and Schuetz, J.D. (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311-318.
189. Wacher, V.J., Wu, C.-Y. and Benet, L.Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein; implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13, 129-134.
190. Wu, C.-Y., Benet, L.Z., Hebert, M.F., Gupta, S.K., Rowland, M., Gomez, D.Y. and Wacher, V.J. (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58, 492-497.
191. Benet, L.Z., Wu, C.Y., Hebert, M.F. and Wacher, V.J. (1996) Intestinal drug-metabolism and antitransport processes - A potential paradigm shift in oral-drug delivery. J. Control. Release 39, 139-143.
192. Harris, R.Z., Benet, L.Z. and Schwartz, J.B. (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50, 222-239.